Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
poor performance status
Description:
A clinical measure of a patient's limited ability to perform daily activities, commonly used to assess fitness for cancer treatment and prognosis.
Related topics:
Lung Cancer Treatments and Mutations (18%),
Lung Cancer Diagnosis and Treatment (15%),
Lung Cancer Research Studies (7%)
OpenAlex ID:
keywords/poor-performance-status
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
2009
·
Akira Inoue
, Kunihiko Kobayashi
, et al.
·
Journal of Clinical Oncology
·
531
A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status
1992
·
NM Bleehen
, DJ Girling
, et al.
·
British Journal of Cancer
·
321
PDF
Management of malignant bowel obstruction
2008
·
Carla Ida Ripamonti
, Alexandra M. Easson
, et al.
·
European Journal of Cancer
·
293
Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial
1996
·
David J Girling
·
The Lancet
·
240
A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)
2009
·
Aminah Jatoi
, Howard L. Ritter
, et al.
·
Lung Cancer
·
232
Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
2011
·
Jaime Gállego Pérez-Larraya
, François Ducray
, et al.
·
Journal of Clinical Oncology
·
219
PDF
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
2019
·
David R. Spigel
, Michael McCleod
, et al.
·
Journal of Thoracic Oncology
·
190
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
2012
·
Siow Ming Lee
, Iftekhar Khan
, et al.
·
The Lancet Oncology
·
190
A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme
1994
·
Glenn S. Bauman
, Laurie E. Gaspar
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
173
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
2018
·
Daichi Fujimoto
, Hiroshige Yoshioka
, et al.
·
Lung Cancer
·
154
Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial
2001
·
John D. Hainsworth
, Howard A. Burris
, et al.
·
Journal of Clinical Oncology
·
154
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
2020
·
Francesco Facchinetti
, Giulia Mazzaschi
, et al.
·
European Journal of Cancer
·
153
PDF
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer
2020
·
Giulia Pasello
, Alberto Pavan
, et al.
·
Cancer Treatment Reviews
·
149
PDF
Possible Role for Tocilizumab, an Anti–Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia
2012
·
Katsutoshi Ando
, Fumiyuki Takahashi
, et al.
·
Journal of Clinical Oncology
·
135
PDF
Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity
2009
·
Paul Hatfield
, Mohan Hingorani
, et al.
·
Radiotherapy and Oncology
·
134
Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status
2009
·
Glenwood Goss
, David Ferry
, et al.
·
Journal of Clinical Oncology
·
124
High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
2015
·
Halfdan Sorbye
, Anca Dragomir
, et al.
·
PLoS ONE
·
122
PDF
Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non–Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial
2021
·
Puneeth Iyengar
, Elizabeth Zhang-Velten
, et al.
·
JAMA Oncology
·
116
Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors
1995
·
Yvan Touitou
, Francis L�vi
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
116
Small cell lung cancer: a slightly less orphan disease after immunotherapy
2021
·
J. Remon
, M. Aldea
, et al.
·
Annals of Oncology
·
112
Optimizing First-Line Treatment Options for Patients with Advanced NSCLC
2005
·
Heather Wakelee
, Chandra P. Belani
·
The Oncologist
·
89
PDF
Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
2019
·
Jordi Remon
, Myung-Ju Ahn
, et al.
·
Journal of Thoracic Oncology
·
88
A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non–Small Cell Lung Cancer
2005
·
Zhongxing Liao
, Ritsuko Komaki
, et al.
·
Clinical Cancer Research
·
87
New Radiotherapy and Chemoradiotherapy Approaches for Non–Small-Cell Lung Cancer
2013
·
Joseph K. Salama
, Everett E. Vokes
·
Journal of Clinical Oncology
·
81
Endoscopic Submucosal Dissection (ESD) with Additional Therapy for Superficial Esophageal Cancer with Submucosal Invasion
2015
·
Atsuki Ikeda
, Namiko Hoshi
, et al.
·
Internal Medicine
·
80
PDF
Show more works
View as search
Works count:
1,192
Citation count:
12,260
Year
Topic
Type